Calcitonin gene-related peptide (CGRP)
Calcitonin gene-related peptide (CGRP) is a neuropeptide and protein target with major relevance in pain biology, neurogenic inflammation, and migraine pathophysiology.
Calcitonin gene-related peptide (CGRP) is a neuropeptide and protein target with major relevance in pain biology, neurogenic inflammation, and migraine pathophysiology. It is widely recognized as a central mediator in migraine and can trigger attacks in susceptible individuals. In biomedical research, CGRP is often studied as part of the TRPV1/CGRP nociceptive axis and broader inflammatory signaling networks that influence sensory transmission, vascular responses, and tissue inflammation.
As a therapeutic target, CGRP has attracted substantial attention because modulation of CGRP signaling can alter headache-related and pain-related phenotypes. Recent studies also extend its relevance beyond migraine to neuropathic pain, post-stroke pain, chronic rhinosinusitis, and regenerative medicine, where CGRP is being incorporated into biomaterial systems to support immunomodulation and osteogenesis.
Where the papers sit
11 papers from the last 6 months study Calcitonin gene-related peptide (CGRP) directly · updated from PubMed 14 Nov 2026
Study type 0 clinical trials · 2 observational · 2 human data · 4 preclinical · 3 unclassified
Themes 3 themes
-
CGRP Migraine Prevention
CGRP-targeted prevention is expanding toward long-term treatment, including patients with epilepsy or prior cardiovascular and cerebrovascular disease. Monoclonal antibodies are being assessed for sustained effectiveness, safety, mood symptoms and outcomes after discontinuation. Clinical guidance and real-world evidence remain uneven, especially for treatment duration and relapse after stopping therapy. Non-CGRP approaches such as lavender-induced orexinergic relief remain complementary.
6 papers · 54.5%
-
CGRP Receptor Pharmacology
CGRP receptor pharmacology is moving from antagonist discovery toward structure-guided design and functional validation. Pharmacophore models aim to improve antagonist selection, while degradation-fragment studies test vascular, immune and receptor activity. Clinical comparison with onabotulinumtoxinA adds cerebrovascular safety to the therapeutic question. How fragment biology and receptor selectivity affect migraine treatment remains open.
3 papers · 27.3%
-
CGRP-Mediated Neuropathic Pain
CGRP suppression is emerging as a shared analgesic strategy for trigeminal neuralgia-like and peripheral neuropathic pain. Botulinum toxin type A reduces pain alongside diminished CGRP release and altered NaV1.7-associated signaling. Bergenin acts through TRPV1/CGRP pathways and neuro-inflammatory mechanisms. The work remains preclinical, with the relative importance of these targets still unresolved.
2 papers · 18.2%
Papers
The 11 papers from the last 6 months that study Calcitonin gene-related peptide (CGRP) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
CGRP Migraine Prevention (6)
- Anxiety and Depression Symptoms During CGRP-Targeted Therapy in Patients with Migraine: A Retrospective Cohort Study from the United Arab Emirates. Neurology and therapy · 11 Nov 2026 PMID 43013187
- Reporting of research priorities in migraine clinical practice guidelines still need improvement-A methodological analysis. PloS one · 30 Oct 2026 PMID 42961969
- Long-term outcome after discontinuation of CGRP monoclonal antibodies therapy for migraine: A narrative review. Journal of the Chinese Medical Association : JCMA · 15 Oct 2026 PMID 42881126
- Preliminary evidence of long-term safety and effectiveness of anti-CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52-week follow-up retrospective study. Epilepsia open · 9 Oct 2026 PMID 42853599
- Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease. Journal of neurology · 15 Sept 2026 PMID 42742761
- An orexinergic circuit driving migraine relief by lavender essential oil. Current biology : CB · 9 Jul 2026 PMID 42425080
CGRP Receptor Pharmacology (3)
- Construction and validation of pharmacophore model of calcitonin gene-related peptide receptor antagonists using ligand- and structure-based approaches. Journal of molecular modeling · 13 Oct 2026 PMID 42867699
- Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program. Cephalalgia : an international journal of headache · 2 Jul 2026 PMID 42390441
- Functional characterisation of dura mater αCGRP degradation fragments at vascular, immune, and CGRP receptor targets. The journal of headache and pain · 22 May 2026 PMID 42168858
CGRP-Mediated Neuropathic Pain (2)
- Botulinum toxin type A attenuates trigeminal neuralgia-like pain by suppressing CGRP release and modulating NaV1.7-associated signaling. The journal of headache and pain · 11 Aug 2026 PMID 42576205
- Bergenin attenuates neuropathic pain by modulation of TRPV1/CGRP signalling and neuro-inflammatory mechanisms. Molecular biology reports · 18 Jun 2026 PMID 42313304
By study type
Observational studies and case reports (2)
- Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease. Journal of neurology · 15 Sept 2026 PMID 42742761
- Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program. Cephalalgia : an international journal of headache · 2 Jul 2026 PMID 42390441
Human data, design not indexed (2)
- Reporting of research priorities in migraine clinical practice guidelines still need improvement-A methodological analysis. PloS one · 30 Oct 2026 PMID 42961969
- Construction and validation of pharmacophore model of calcitonin gene-related peptide receptor antagonists using ligand- and structure-based approaches. Journal of molecular modeling · 13 Oct 2026 PMID 42867699
Preclinical: animal, cell and lab studies (4)
- Botulinum toxin type A attenuates trigeminal neuralgia-like pain by suppressing CGRP release and modulating NaV1.7-associated signaling. The journal of headache and pain · 11 Aug 2026 PMID 42576205
- An orexinergic circuit driving migraine relief by lavender essential oil. Current biology : CB · 9 Jul 2026 PMID 42425080
- Bergenin attenuates neuropathic pain by modulation of TRPV1/CGRP signalling and neuro-inflammatory mechanisms. Molecular biology reports · 18 Jun 2026 PMID 42313304
- Functional characterisation of dura mater αCGRP degradation fragments at vascular, immune, and CGRP receptor targets. The journal of headache and pain · 22 May 2026 PMID 42168858
Unclassified: not yet indexed with MeSH (3)
- Anxiety and Depression Symptoms During CGRP-Targeted Therapy in Patients with Migraine: A Retrospective Cohort Study from the United Arab Emirates. Neurology and therapy · 11 Nov 2026 PMID 43013187
- Long-term outcome after discontinuation of CGRP monoclonal antibodies therapy for migraine: A narrative review. Journal of the Chinese Medical Association : JCMA · 15 Oct 2026 PMID 42881126
- Preliminary evidence of long-term safety and effectiveness of anti-CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52-week follow-up retrospective study. Epilepsia open · 9 Oct 2026 PMID 42853599
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-09-17 by GPT. Drafted by language models from published abstracts; not medical advice.